Akèy › Kansè nan tete › Arizona › Tucson
Etid klinik pou Kansè nan tete nan Tucson, AZ
20 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Tucson (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Ap rekriteFaz 3
- The University of Arizona Cancer Center - North Campus ( Site 0055), Tucson
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Ap rekriteFaz 2
- The University of Arizona Cancer Center - North Campus, Tucson
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- University of Arizona Cancer Center ( Site 0035), Tucson
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Ap rekrite
- University of Arizona Cancer Center, Tucson
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- The University of Arizona Cancer Center - North Campus, Tucson
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Arizona Clinical Research Center, Inc., Tucson
- University of Arizona Cancer Center, Tucson
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Ap rekriteFaz 1/2
- University of Arizona Cancer Center, Tucson
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Ap rekriteFaz 1/2
- University of Arizona, Tucson
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Ap rekriteFaz 3
- University of Arizona-Cancer Center, Tucson
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Ap rekriteFaz 3
- Tucson Medical Center HealthCare, Tucson
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- USOR Arizona Oncology Associates, Tucson
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Ap rekriteFaz 2
- University of Arizona Cancer Center - Prevention Research Clinic, Tucson
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Ap rekriteFaz 3
- University of Arizona - Cancer Center, Tucson
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- The University of Arizona Cancer Center, Tucson
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Ap rekriteFaz 1
- The University of Arizona Cancer Center, Tucson
High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)
Ap rekriteVolontè an sante akeyi
- University of Arizona, Tucson
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Ap rekriteEtid obsèvasyon
- Arizona Oncology Associates, PC - HOPE, Tucson
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Ap rekriteFaz 2
- Arizona Oncology Associates, Tucson
Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss
Ap rekrite
- University of Arizona, Tucson
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Ap rekriteEtid obsèvasyon
- Arizona Oncology, Tucson
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Durham, NC64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
Lòt etid nan Tucson
- Obèsite18 etid
- Kansè Poumon ki pa ti selil17 etid
- Sipwa15 etid
- Kansè Metastatik14 etid
- Kansè (tout kalite)12 etid
- Maladi kadyovaskilè12 etid
- Kansè kolorektal11 etid
- Kansè pwostat11 etid
- Dyabèt Tip 211 etid
- Maladi fwa steatotik10 etid
- Ensifizyans kadyak10 etid
- Hypertension artérielle10 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.